As of Feb 21, 2025, Novartis AG's Discounted Cash Flow (DCF) valuation estimates its share price at $152.6. This suggests it may be undervalued by 39.5% compared to its current price of around $109.4, using a WACC of 6.8% and growth rates of 3.0%.
As of Feb 21, 2025, Novartis AG's Weighted Average Cost of Capital (WACC) is approximately 6.8%.
As of Feb 21, 2025, Novartis AG's Enterprise Value (EV) is approximately $321.1B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.